Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
Published Online: 2023-05-?
Journal: The Lancet•Publisher: Elsevier BV
Authors: Ahsan Arozullah•David Ilson•Diarmuid Moran•Eric Van Cutsem•Florian Lordick•Giuseppe Aprile•Jaffer A Ajani•Jianming Xu•Jianning Yang•Joseph Chao•Jung Wook Park•Kohei Shitara•Manish A Shah•Mok Oh•Peter Enzinger•Pranob Bhattacharya•Roberto Pazo-Cid•Rui-Hua Xu•Yoon-Koo Kang•Yung-Jue Bang
